Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide versus dulaglutide as add-on to metformin in type 2 diabetes
2014-005375-91Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of semaglutide and dulaglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Aug 2015; status: completed.
02
Drugs
semaglutidedulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-005375-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005375-91.